Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy

Gelijkaardige items

• Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
  door: Mukherjee, Manali, et al.
  Gepubliceerd in: (2017)
• Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
  door: Gupta, Atul, et al.
  Gepubliceerd in: (2019)
• Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
  door: Yancey, Steven W., et al.
  Gepubliceerd in: (2019)
• Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
  door: Magnan, A., et al.
  Gepubliceerd in: (2016)
• Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
  door: Howarth, Peter, et al.
  Gepubliceerd in: (2020)